Fate Therapeutics, Inc. (FATE)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
3.02 USD
-0.08
(-2.581%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.02 0.00 (0.000%) ⇩ (July 13, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:42 a.m. EDT
The long-term outlook is severely compromised by a brutal four-year streak of declining annual returns, dragging the stock down nearly 34% from its peak despite a massive historical run-up. This multi-year decline signals a structural deterioration in the business's ability to generate value, overriding any potential catalysts. While the balance sheet remains technically healthy with low debt relative to equity, the company is burning through cash rapidly with negative free cash flow and shrinking revenues, leaving it dependent on capital markets for survival. The short-term picture offers a speculative bounce opportunity given the recent FDA approvals and insider selling at lows, but the lack of a dividend and the persistent fundamental bleed make this a high-risk hold rather than a buy. The statistical forecast models also lean slightly negative, confirming the tension between fleeting clinical headlines and the harsh reality of the stock's trajectory. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.473678 |
| MSTL_79_115 | 0.507370 |
| MSTL | 0.511871 |
| MSTL_79 | 0.513713 |
| AutoETS | 0.517578 |
| AutoARIMA | 0.517909 |
| MSTL_115 | 0.525962 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 4.57 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.365 |
| Excess Kurtosis | -0.70 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 42.728 |
| Revenue per Share | 0.053 |
| Market Cap | 352,008,736 |
| Forward P/E | -3.05 |
| Beta | 2.52 |
| Website | https://www.fatetherapeutics.com |
As of July 11, 2026, 3:42 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts at strikes below the current price across multiple expirations. Call activity is sparse and concentrated near the money, while put volume significantly outweighs call volume in terms of implied positioning weight, suggesting a bearish bias among retail traders.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.7192984 |
| Address1 | 12,278 Scripps Summit Drive |
| All Time High | 121.16 |
| All Time Low | 0.66 |
| Ask | 3.62 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 5,686,160 |
| Average Daily Volume3 Month | 4,016,836 |
| Average Volume | 4,016,836 |
| Average Volume10Days | 5,686,160 |
| Beta | 2.52 |
| Bid | 2.32 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 1.546 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.02 |
| Current Ratio | 5.85 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.23 |
| Day Low | 2.8 |
| Debt To Equity | 42.728 |
| Display Name | Fate Therapeutics |
| Earnings Call Timestamp End | 1,715,288,400 |
| Earnings Call Timestamp Start | 1,715,288,400 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,451,400 |
| Earnings Timestamp Start | 1,786,451,400 |
| Ebitda | -125,838,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.018 |
| Enterprise To Revenue | 40.211 |
| Enterprise Value | 253,974,736 |
| Eps Current Year | -1.03889 |
| Eps Forward | -0.98875 |
| Eps Trailing Twelve Months | -1.09 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.2252 |
| Fifty Day Average Change | 0.79480004 |
| Fifty Day Average Change Percent | 0.3571814 |
| Fifty Two Week Change Percent | 171.92984 |
| Fifty Two Week High | 3.23 |
| Fifty Two Week High Change | -0.21000004 |
| Fifty Two Week High Change Percent | -0.065015495 |
| Fifty Two Week Low | 0.91 |
| Fifty Two Week Low Change | 2.11 |
| Fifty Two Week Low Change Percent | 2.3186812 |
| Fifty Two Week Range | 0.91 - 3.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,380,634,200,000 |
| Float Shares | 101,864,569 |
| Forward Eps | -0.98875 |
| Forward P E | -3.0543616 |
| Free Cashflow | -50,068,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 161 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -81,150,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01166 |
| Held Percent Institutions | 0.72995 |
| Implied Shares Outstanding | 116,559,186 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California. |
| Long Name | Fate Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 352,008,736 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_39268712 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -129,907,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 361,333,476 |
| Number Of Analyst Opinions | 9 |
| Open | 3.0799 |
| Operating Cashflow | -103,097,000 |
| Operating Margins | -25.40416 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 875 1800 |
| Post Market Change | -0.000099897385 |
| Post Market Change Percent | -0.0033078603 |
| Post Market Price | 3.0199 |
| Post Market Time | 1,783,987,124 |
| Previous Close | 3.1 |
| Price Eps Current Year | -2.9069488 |
| Price Hint | 4 |
| Price To Book | 1.9534281 |
| Price To Sales Trailing12 Months | 55.73286 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.746 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.08333 |
| Region | US |
| Regular Market Change | -0.0799999 |
| Regular Market Change Percent | -2.58064 |
| Regular Market Day High | 3.23 |
| Regular Market Day Low | 2.8 |
| Regular Market Day Range | 2.8 - 3.23 |
| Regular Market Open | 3.0799 |
| Regular Market Previous Close | 3.1 |
| Regular Market Price | 3.02 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 6,041,440 |
| Return On Assets | -0.25294 |
| Return On Equity | -0.55502 |
| Revenue Growth | -0.203 |
| Revenue Per Share | 0.053 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 116,559,186 |
| Shares Percent Shares Out | 0.0638 |
| Shares Short | 7,432,049 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 10,697,112 |
| Short Name | Fate Therapeutics, Inc. |
| Short Percent Of Float | 0.0723 |
| Short Ratio | 1.54 |
| Source Interval | 15 |
| State | CA |
| Symbol | FATE |
| Target High Price | 8.0 |
| Target Low Price | 2.2 |
| Target Mean Price | 5.41111 |
| Target Median Price | 6.0 |
| Total Cash | 174,822,000 |
| Total Cash Per Share | 1.5 |
| Total Debt | 76,785,000 |
| Total Revenue | 6,316,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.09 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.4657 |
| Two Hundred Day Average Change | 1.5543 |
| Two Hundred Day Average Change Percent | 1.0604489 |
| Type Disp | Equity |
| Volume | 6,041,440 |
| Website | https://www.fatetherapeutics.com |
| Zip | 92,131 |